Pfizer (PFE) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cowen Remains Positive as Pfizer (PFE) Reports a 3Q Beat and raise
October 27, 2015 4:23 PM EDTCowen reiterated an Outperform rating and $43.00 price target on Pfizer (NYSE: PFE) following the company's 3Q earnings results. Q3 sales of $12,087MM (-2%) were $527MM above consensus. EPS of $0.60 (+5%) was $0.09 ahead of consensus. 2015 EPS guidance was raised to $2.16-2.20 from prior $2.04-2.10 range.... More
